In silico toxicology and AI at ACT 2026

Nov 15–18, 2026 San Antonio, TX ~1.4k attendees Website

34 organizations at ACT 2026 present work in in silico toxicology and AI: 24 service, testing and tools companies, 5 drug developers and 5 universities, agencies and non-profits. Between them they bring 83 presentations to the program. Most represented: Johnson & Johnson (8 on the program), Boehringer Ingelheim (4 on the program), HESI (4 on the program). As of Oct 8, 2026.

All 231 organizations at ACT 2026 →

Showing 1–8 of 34 organizations

Organization	ACT 2026 Attendance
Johnson & Johnson New Brunswick, NJ
jnj.com Pharmaceutical companies Healthcare company whose Innovative Medicine arm, formerly Janssen, discovers, develops and markets prescription medicines.	Talk Sun Nov 15 8:00am–8:05am Part of Working with Global Regulators for Streamlined Nonclinical Development (CE4) Introduction (CE4-1) Regulatory Session Sun Nov 15 8:00am–11:30am Working with Global Regulators for Streamlined Nonclinical Development (CE4) Regulatory · with MEC Regulatory & Toxicology Consulting 8:00amIntroduction (CE4-1)Johnson & Johnson 8:05amTop Tips for Successful Nonclinical Regulatory Interaction (CE4-2)Charles River 8:30amIdeal Interaction During Drug Development: FDA Regulator's Perspective (CE4-3)U.S. Food and Drug Administration 9:00amIdeal Interaction During Drug Development: European Regulator's Perspective (CE4-4)Medicines Evaluation Board 10:00amSponsor Strategies for Successful Regulatory Agency Interactions (CE4-5)Lilly 10:30amInteractive Workshop: Practical Case Studies to Model Successful Regulatory Agency Interactions (CE4-6)MEC Regulatory & Toxicology Consulting Talk Sun Nov 15 9:00am–9:30am Part of The ABCs of EFDs: A Modern Guide to Embryofetal Development Testing (CE3) Conducting an EFD Study: The Essentials of Getting it Right (CE3-4) DART Talk Sun Nov 15 3:00pm–3:20pm Part of Immunotherapies and Collaborative Approaches to Immunosafety Assessment (CE6) Effectively Evaluating, Understanding, and Communicating the Risky Behavior of Immunotherapies: The Complex and Diverse Role of a Project (Program) Toxicologist (CE6-5) Immunotoxicology Talk Mon Nov 16 2:00pm–2:05pm Part of Navigating Safety Signals and Clinical Holds: Lessons Learned from Nonclinical and Clinical Development (S06) Introduction (S06-1) Translational safety Session Mon Nov 16 2:00pm–5:00pm Navigating Safety Signals and Clinical Holds: Lessons Learned from Nonclinical and Clinical Development (S06) Translational safety 2:00pmIntroduction (S06-1)Johnson & Johnson 2:05pmDe-risking of Nonclinical Renal Safety Signals through Investigative Studies and Robust Clinical Monitoring (S06-2)Bristol Myers Squibb 2:40pmDILI Whodunnit: Responding to Drug Induced Liver Injury during TAK-994 Clinical Trials (S06-3)Takeda 3:45pmClinical Holds in the Development of Novel Genetic Medicines (S06-4)Bioepisteme 4:20pmProspective and Retrospective Risk Assessments of Safety Signals for a Rare Disease Biotherapeutic (S06-5)Amgen Poster Mon Nov 16 5:00pm–6:30pm Validation of Organ-Specific Risk Estimates Derived from a Gene-Based Machine Learning Algorithm (P447) Nelson Exhibit Ballroom · Poster P447 In silico and AI Talk Tue Nov 17 3:45pm–4:15pm Part of The Evolving Landscape of Secondary Pharmacology and Off-Target Assessments in Pharmaceutical Development (S10) Evolving Selectivity Assessment of Biologic Products with Cell-Based Protein Arrays and Derisking Strategies (S10-4) Biologics and new modalities · Safety pharmacology Talk Wed Nov 18 2:25pm–2:45pm Part of Invisible Ingredients, Critical Functions: The Risk Narrative around Excipients and PFAS (S17) Risk Communication and Perception of Forever Chemicals and the Consequences for Pharma (S17-2) Chemical risk assessment
Boehringer Ingelheim Ingelheim, Germany
boehringer-ingelheim.com Pharmaceutical companies Family-owned German pharmaceutical company developing human medicines and animal health products.	Session Sun Nov 15 8:00am–11:30am First-in-Human Dose Selection: Translational Strategies and Special Considerations across Modalities and Organ Systems (CE1) Translational safety · with Novartis 8:00amFoundational Approaches to FIH Dose Selection (CE1-1)White Oak Regulatory Tox 8:20amModel-Informed Approaches to FIH Dose Prediction (CE1-2)Bedard ADME-Tox Solutions, Tango Therapeutics 8:45amCNS-Delivered Therapeutics: Anatomic, Physiologic, and Modality-Specific Considerations (CE1-3)Akkeri 9:10amInter-Species Dose Extrapolation for Ocular Therapeutics: Translational Frameworks for Eye-Delivered Products (CE1-4)Novartis 10:00amCrossing the Species Divide in Inhaled Dosing (CE1-5)Novartis 10:25amInteractive Session: Hypothetical Challenge Scenarios in FIH Setting (CE1-6)Boehringer Ingelheim Session Sun Nov 15 8:00am–11:30am From Predictive Models to Collaborative Intelligence: The Role of Agentic AI in the Future of Toxicology (CE2) In silico and AI · with Human Chemical 8:00amWelcome and Course Overview (CE2-1)Human Chemical 8:05amAgentic AI 101: A Primer for Drug Discovery and Development Toxicologists (CE2-2)Taiho Oncology 8:30amAgentic AI Frameworks for Predictive Toxicology-Based Literature Searches (CE2-3)Coincidence Labs 9:00amSynthesizing Experimental Results and In-Silico Predictions for Autonomous Hypothesis Generation (CE2-4)Human Chemical 10:00amLeveraging Agentic AI to Reassess and Optimize Previously Failed Compounds (CE2-5)Ignota Labs 10:30amChemistry Foundation Models for Optimal Drug Design (CE2-6)deepmirror Talk Sun Nov 15 10:25am–11:30am Part of First-in-Human Dose Selection: Translational Strategies and Special Considerations across Modalities and Organ Systems (CE1) Interactive Session: Hypothetical Challenge Scenarios in FIH Setting (CE1-6) Translational safety Poster Mon Nov 16 5:00pm–6:30pm IL-10–Associated Thrombocytopenia Is Not Mediated by Direct Platelet Effects (P129) Nelson Exhibit Ballroom · Poster P129 Immunotoxicology · Pathology Poster Mon Nov 16 5:00pm–6:30pm Strengthening Regulatory Confidence in Liver MPS: Insights from The 3Rs Collaborative’s & FDA CDER’s Cross Platform DILI Project (P213) Nelson Exhibit Ballroom · Poster P213 New approach methods · Regulatory Session Tue Nov 17 9:00am–12:00pm Next-Generation Liver Toxicity Assessment: Integrating Human-Relevant NAMs, AI, and Exposure Modeling (S07) New approach methods · In silico and AI · with Physicians Committee for Responsible Medicine 9:00amIntroduction (S07-1)Physicians Committee for Responsible Medicine 9:05amAn Integrated NAM Platform Combining Bioactivity Prediction with PBPK and Literature Intelligence for Chemical Liver Toxicity Assessment (S07-2)Human Chemical 9:30amMulticellular Hepatic In Vitro Models Using NANOSTACKS™: Flow-Driven Differential Toxicity and Human-Relevant Drug Response Prediction (S07-3)Revivocell 9:55amAI-Enabled, Exposure-Anchored DILI Prediction Using Human 3D Liver Microtissues (S07-4)InSphero 10:45amFrom Exposure Dynamics to Uncertainty: A Hybrid Framework for Drug-Induced Liver Injury Prediction (S07-5)ESQlabs 11:25amNovel Optical Techniques to Study Hepatic Microplastic Pollution: Optical Imaging as a Powerful New Approach Methodology (S07-6)University of New Mexico Talk Wed Nov 18 2:00pm–2:20pm Part of The Versatile Toxicologist: How to Leverage Expertise into Opportunity (S16) Conventional and Unconventional Trajectories to a Toxicologist Career in the Pharmaceutical Sector (S16-1) Careers
HESI Washington, DC	◇Silver Supporter
hesiglobal.org Societies and non-profitsSilver Supporter Non-profit running collaborative scientific programs among industry, government and academic scientists on human health and environmental safety questions.	Poster Mon Nov 16 5:00pm–6:30pm Expectations and Opinions on an ICH S7A Revision: Stakeholder Survey Results (P207) Nelson Exhibit Ballroom · Poster P207 Safety pharmacology · Regulatory Talk Wed Nov 18 9:00am–9:15am Part of The Future of Nonclinical Carcinogenicity Testing: NAMs in a Weight-of-Evidence Paradigm Shift (S15) From Rodent Bioassays to Mechanistic Evidence: The Future of Carcinogenicity Assessment (S15-1) Genetic toxicology Session Wed Nov 18 9:00am–12:00pm The Future of Nonclinical Carcinogenicity Testing: NAMs in a Weight-of-Evidence Paradigm Shift (S15) Genetic toxicology · New approach methods · with White Oak Regulatory Tox 9:00amFrom Rodent Bioassays to Mechanistic Evidence: The Future of Carcinogenicity Assessment (S15-1)HESI 9:15amCarcinogenicity Assessments Based on a Weight of Evidence Approach and the Role of NAMs in Supporting This Approach (S15-2)White Oak Regulatory Tox 9:45amIntegrating Error-Corrected Sequencing into OECD Test Guidelines: Advancing Precision Mutagenesis in Regulatory Toxicology (S15-3)Health Canada 10:45amAssessing Clonal Expansion of Cancer Driver Mutants as an Early Cancer Biomarker (S15-4)U.S. Food and Drug Administration 11:15amIndustry Perspectives on Advanced Methods for Carcinogenicity Risk Assessment (S15-5)GSK Talk Wed Nov 18 2:30pm–2:55pm Part of Hot Topics (S18) Benchmark Dose Modeling: Advancing Transparency and Next-Generation Applications in Risk Assessment (S18-3) In silico and AI · Chemical risk assessment Talk Wed Nov 18 2:55pm–3:15pm Part of Hot Topics (S18) Emerging Insights on QTc Risks in Targeted Protein Degraders (S18-4) Safety pharmacology
National Institutes of Health Bethesda, MD
nih.gov Government agencies and regulators US federal medical research agency that funds and conducts biomedical research across 27 institutes and centers.	Session Sun Nov 15 1:00pm–4:30pm Quantitative Structure–Activity Relationship Demystified: Foundations, Best Practices, Regulatory Use, and Practical Applications (CE8) In silico and AI · with JRF Global 1:00pmIntroduction (CE8-1)JRF Global 1:05pmFoundations of QSAR: Principles, Model Types, and the Science Behind Structure–Activity Relationships (CE8-2)JRF Global 1:30pmBuilding Reliable QSAR Models: Standardized Workflows, Data Quality, and Practical Modeling Considerations (CE8-3)National Institutes of Health 2:00pmIntegrating QSAR Modeling and Weight-of-Evidence into Read-Across Frameworks (CE8-4)Sciome 3:00pmOECD QSAR Toolbox in Practice: Chemical Profiling, Category Formation, Read-Across, Data Gap Filling, and Interpretation (CE8-5)Physicians Committee for Responsible Medicine Talk Sun Nov 15 1:30pm–2:00pm Part of Quantitative Structure–Activity Relationship Demystified: Foundations, Best Practices, Regulatory Use, and Practical Applications (CE8) Building Reliable QSAR Models: Standardized Workflows, Data Quality, and Practical Modeling Considerations (CE8-3) In silico and AI Talk Mon Nov 16 9:00am–9:05am Part of The Role of Professional Judgment in Toxicology amidst the Rise of Artificial Intelligence and Computational Tools (S02) Introduction (S02-1) In silico and AI Session Mon Nov 16 9:00am–12:00pm The Role of Professional Judgment in Toxicology amidst the Rise of Artificial Intelligence and Computational Tools (S02) In silico and AI · with Certara 9:00amIntroduction (S02-1)National Institutes of Health 9:05amEnhancing Toxicological Literature Review through AI and Expert Insight (S02-2)ToxStrategies 9:25amNo Spreadsheet Left Unharmonized: A Human-in-the-Loop Framework for AI-Assisted Toxicology Data Extraction and Standardization (S02-3)Certara 9:50amWhen AI Gets It Wrong: Interpreting Predictive Models from Omics and High-Content Data (S02-4)Human Chemical 10:45amChemical Similarity in Practice: Navigating Endpoint-Agnostic and Endpoint-Specific Approaches (S02-5)National Institutes of Health 11:15amIntegrating Artificial Intelligence and Professional Expertise in Structure-Activity Assessments (S02-6)Inductive Bio Talk Mon Nov 16 10:45am–11:15am Part of The Role of Professional Judgment in Toxicology amidst the Rise of Artificial Intelligence and Computational Tools (S02) Chemical Similarity in Practice: Navigating Endpoint-Agnostic and Endpoint-Specific Approaches (S02-5) In silico and AI Talk Wed Nov 18 3:45pm–4:15pm Part of Hot Topics (S18) Winning the Rat Race: Repurposing GLP-1 Receptor Agonists for Addiction (S18-5) Neurotoxicology
Human Chemical
humanchemical.com Software and AI companies Builds specialized AI agents for toxicology and regulatory work: in silico hazard prediction, PBPK modeling and drafting regulatory documents.	Session Sun Nov 15 8:00am–11:30am From Predictive Models to Collaborative Intelligence: The Role of Agentic AI in the Future of Toxicology (CE2) In silico and AI · with Boehringer Ingelheim 8:00amWelcome and Course Overview (CE2-1)Human Chemical 8:05amAgentic AI 101: A Primer for Drug Discovery and Development Toxicologists (CE2-2)Taiho Oncology 8:30amAgentic AI Frameworks for Predictive Toxicology-Based Literature Searches (CE2-3)Coincidence Labs 9:00amSynthesizing Experimental Results and In-Silico Predictions for Autonomous Hypothesis Generation (CE2-4)Human Chemical 10:00amLeveraging Agentic AI to Reassess and Optimize Previously Failed Compounds (CE2-5)Ignota Labs 10:30amChemistry Foundation Models for Optimal Drug Design (CE2-6)deepmirror Talk Sun Nov 15 8:00am–8:05am Part of From Predictive Models to Collaborative Intelligence: The Role of Agentic AI in the Future of Toxicology (CE2) Welcome and Course Overview (CE2-1) In silico and AI Talk Sun Nov 15 9:00am–9:30am Part of From Predictive Models to Collaborative Intelligence: The Role of Agentic AI in the Future of Toxicology (CE2) Synthesizing Experimental Results and In-Silico Predictions for Autonomous Hypothesis Generation (CE2-4) In silico and AI Talk Mon Nov 16 9:50am–10:15am Part of The Role of Professional Judgment in Toxicology amidst the Rise of Artificial Intelligence and Computational Tools (S02) When AI Gets It Wrong: Interpreting Predictive Models from Omics and High-Content Data (S02-4) In silico and AI Talk Tue Nov 17 9:05am–9:30am Part of Next-Generation Liver Toxicity Assessment: Integrating Human-Relevant NAMs, AI, and Exposure Modeling (S07) An Integrated NAM Platform Combining Bioactivity Prediction with PBPK and Literature Intelligence for Chemical Liver Toxicity Assessment (S07-2) New approach methods · In silico and AI
ToxStrategies Rancho Santa Margarita, CA	◆Gold Supporter
toxstrategies.com ConsultanciesGold Supporter Consultancy, part of BlueRidge Life Sciences, that plans and manages nonclinical programs across small molecules, biologics and cell and gene therapies.	Booth Exhibiting at Booth 606 Mon, Nov 169:30am–6:30pmTue, Nov 178:00am–4:30pm Talk Mon Nov 16 9:05am–9:25am Part of The Role of Professional Judgment in Toxicology amidst the Rise of Artificial Intelligence and Computational Tools (S02) Enhancing Toxicological Literature Review through AI and Expert Insight (S02-2) In silico and AI Talk Mon Nov 16 9:45am–10:15am Part of Beyond the Vessel Wall: Translational Insights into Vascular Inflammation (S03) A Regulatory Perspective (S03-3) Regulatory Poster Mon Nov 16 5:00pm–6:30pm Development of an Occupational Exposure Limit (OEL) and Permissible Daily Exposure (PDE) Limit to Support Manufacturing of an Intermediate Antibody Using Read-Across (P413) Nelson Exhibit Ballroom · Poster P413 Chemical risk assessment · In silico and AI
Gilead Sciences Foster City, CA
gilead.com Pharmaceutical companies Biopharmaceutical company with marketed HIV, liver disease and oncology medicines; presents on NAMs and extractables and leachables safety.	Talk Sun Nov 15 1:30pm–2:00pm Part of Beyond Animal Models: Navigating New Approach Methodologies in Modern Drug Development with Case Study Examples (CE5) New Approach Methodologies (NAMs): Role of Nonclinical Scientists (CE5-3) New approach methods Session Tue Nov 17 2:00pm–5:00pm Safety Assessment of Extractables and Leachables under the New ICH Q3E Guideline (S11) Chemical risk assessment · Regulatory · with U.S. Food and Drug Administration 2:00pmWelcome (S11-1)Gilead Sciences 2:05pmIntroduction to the ICH Q3E Draft Guideline: Extractables & Leachables - A Pharmaceutical Industry Perspective (S11-2)Bristol Myers Squibb 2:40pmAssessing the Data Landscape of Extractables and Leachables and Implications for Read Across Strategies (S11-3)Instem 3:45pmSafety Assessment Principles for Extractable/Leachables from an FDA Perspective (S11-4)U.S. Food and Drug Administration 4:15pmApplication of Read-Across Methodology for Extractables and Leachables to Derive a Class-based Acceptable Exposure Level for Cyclic Siloxanes (S11-5)Gilead Sciences Talk Tue Nov 17 2:00pm–2:05pm Part of Safety Assessment of Extractables and Leachables under the New ICH Q3E Guideline (S11) Welcome (S11-1) Chemical risk assessment Talk Tue Nov 17 4:15pm–4:45pm Part of Safety Assessment of Extractables and Leachables under the New ICH Q3E Guideline (S11) Application of Read-Across Methodology for Extractables and Leachables to Derive a Class-based Acceptable Exposure Level for Cyclic Siloxanes (S11-5) Chemical risk assessment · In silico and AI
InSphero Brunswick, ME
insphero.com Animal and in vitro model suppliers Makes 3D spheroid microtissue models, such as liver and gastrointestinal models, for in vitro safety and efficacy testing in drug discovery.	Booth Exhibiting at Booth 103 Mon, Nov 169:30am–6:30pmTue, Nov 178:00am–4:30pm Poster Mon Nov 16 5:00pm–6:30pm Early Safety Assessment in Liver Microtissues Using Low-Input RNA-Seq and Mechanistic Studies across Species and Compound Analogs (P415) Nelson Exhibit Ballroom · Poster P415 New approach methods Talk Tue Nov 17 9:55am–10:15am Part of Next-Generation Liver Toxicity Assessment: Integrating Human-Relevant NAMs, AI, and Exposure Modeling (S07) AI-Enabled, Exposure-Anchored DILI Prediction Using Human 3D Liver Microtissues (S07-4) New approach methods · In silico and AI Talk Wed Nov 18 12:00pm–12:55pm 3D InSight Liver and Gastrointestinal Models: Comprehensive Tools for Nonclinical Safety Assessment Grand Oaks Ballroom P New approach methods

Instantly find 20 buyers in in silico toxicology and AI

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the American College of Toxicology (ACT). Organization details are derived from ACT’s published program, exhibitor floor plan and supporter list, and each organization’s own website. Submit a correction

Instantly find 20 buyers in in silico toxicology and AI

Browse ACT 2026 by